project id: TCGA-PRAD; case submitter id: TCGA-EJ-A8FS; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.54; rna integrity number: 8.1; age at index: 66; days to birth: -24380; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 24380; ajcc clinical m: M0; ajcc clinical t: T3a; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 266.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 126; initial weight: 130.0; sample id: 76b87139-e8f9-4221-b63e-940848e8c52c; sample submitter id: TCGA-EJ-A8FS-01A; portion id: 357ab0c9-dff8-421b-bc47-d414a59af60b; portion submitter id: TCGA-EJ-A8FS-01A-11; slide id: 16b8b31a-59de-4159-ade0-8d398dfb9414; slide submitter id: TCGA-EJ-A8FS-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 50.0; percent stromal cells: 0.0; percent tumor cells: 50.0; percent tumor nuclei: 60.0; section location: TOP;